These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 16322294)

  • 1. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.
    Schneider PM; Metzger R; Schaefer H; Baumgarten F; Vallbohmer D; Brabender J; Wolfgarten E; Bollschweiler E; Baldus SE; Dienes HP; Hoelscher AH
    Ann Surg; 2008 Dec; 248(6):902-8. PubMed ID: 19092334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
    Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
    Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T; Nishina T; Hyodo I; Moriwaki T; Endo S; Nasu J; Hori S; Matsuura B; Hiasa Y; Onji M
    Oncology; 2009; 76(5):342-9. PubMed ID: 19307741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
    Grimminger P; Vallböhmer D; Hoffmann A; Schulte C; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R; Brabender J
    J Surg Oncol; 2009 Nov; 100(6):447-51. PubMed ID: 19653263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
    Takatori H; Natsugoe S; Okumura H; Matsumoto M; Ishigami S; Owaki T; Aikou T
    Oncol Rep; 2005 Apr; 13(4):697-701. PubMed ID: 15756444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
    Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
    Kulke MH; Odze RD; Mueller JD; Wang H; Redston M; Bertagnolli MM
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1579-86. PubMed ID: 15173710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].
    Hölscher AH; Metzger R; Schneider PM
    Zentralbl Chir; 2000; 125(4):319-25. PubMed ID: 10829311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.